Harmony Biosciences Holdings (HRMY)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 190,826 | 197,153 | 120,186 | 87,528 | 16,986 |
| Long-term debt | US$ in thousands | 163,016 | 178,566 | 189,647 | 189,984 | 194,250 |
| Total stockholders’ equity | US$ in thousands | 659,155 | 466,992 | 402,838 | 186,507 | 97,180 |
| Return on total capital | 23.21% | 30.54% | 20.29% | 23.25% | 5.83% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $190,826K ÷ ($163,016K + $659,155K)
= 23.21%
Harmony Biosciences Holdings has shown a fluctuating trend in its return on total capital over the years based on the provided data. Starting at 5.83% on December 31, 2020, the return saw a significant increase to 23.25% by December 31, 2021. Subsequently, there was a slight decrease to 20.29% by December 31, 2022. However, the return rebounded strongly to 30.54% by December 31, 2023, indicating improved capital efficiency. The return then slightly decreased to 23.21% by December 31, 2024. Overall, the company's return on total capital demonstrates variability, with some periods of substantial growth, suggesting fluctuations in capital utilization efficiency and profitability over the years.
Peer comparison
Dec 31, 2024